Ben Childers, MD
Plastic and Reconstructive Surgery · Riverside, CANPI 1932287471
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,301 of the $3,651 with a category attached, or 63.0%. AbbVie accounts for 79.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $1,002 and has fallen 58.3% since, to $418 in 2025.
Across 78 payments — averaging $46.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Integra Lifesciences Corporation$255
- Abbott$126
- Merz North America, Inc.$125
- Polynovo North America LLC$69
- Sientra, Inc.$64
- plus $127 from 5 others
What the payments were for
- Speaking & faculty fees$2,30163%
- Food & beverage$1,34937%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $2,885 |
| Integra Lifesciences Corporation | 9 | $255 |
| Abbott | 6 | $126 |
| Merz North America, Inc. | 1 | $125 |
| Polynovo North America LLC | 2 | $69 |
| Sientra, Inc. | 1 | $64 |
| Aroa Biosurgery Incorporated | 1 | $45 |
| Mentor Worldwide LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Avanos Medical | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,651 in reported general payments places this provider in the 60th percentile of 349 plastic and reconstructive surgery providers in California.
See all plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 97 | $616 |
| Tramadol Hcl | 56 | $149 |
| Ondansetron Hcl | 50 | $130 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $106 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $95 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Riverside
- Joseph KuRiverside$33K
- Mark SuskiThousand Oaks$294K
- Corey MaasSan Francisco$286K
- Arian MowlaviLaguna Beach$250K
- Charles LeeSan Francisco$200K
- David SieberSan Francisco$195K
- David KulberLos Angeles$194K
- Matthew NykielUpland$181K
- Subhas GuptaLoma Linda$178K
- Jeffrey HammoudehLos Angeles$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.